Counterfeit Medicines: A Major Public Health Concern and Effective Strategies to Combat the Crisis

Counterfeit, falsified and substandard medicines remain a major public health concern worldwide, including in India. These products may contain incorrect, insufficient or harmful ingredients, fail to provide the intended therapeutic effect, cause direct toxicity and contribute to loss of confidence in healthcare systems. The scale of the problem varies across countries and medicine categories, while differences in sampling and testing methods make prevalence estimates difficult to compare. This review discusses the terminology and classification of poor-quality medicines and summarises evidence on their global prevalence, with attention to findings from Africa and India. It examines contributing factors such as weaknesses in regulatory oversight, manufacturing and quality control, gaps in supply-chain traceability, limited access to affordable quality-assured medicines, unauthorised sales and inadequate reporting. The review also considers consequences for treatment outcomes, patient safety, healthcare costs, antimicrobial resistance and public trust. Strategies to address the problem include stronger regulatory frameworks, good manufacturing practices, secure procurement and distribution, traceability technologies, post-marketing surveillance, risk-based sampling, laboratory testing, oversight of online sales, professional training, public awareness and international information sharing. Digital authentication and portable screening tools can support detection, but should complement rather than replace appropriate quality testing and regulatory investigation. Persistent challenges include unequal regulatory capacity, complex cross-border supply chains, under-reporting and barriers to accessing reliable medicines. A coordinated, evidence-informed approach involving regulators, manufacturers, healthcare professionals and the public is needed to prevent, detect and respond to poor-quality medicines and improve access to safe, effective and quality-assured medical products.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-13
DOI
https://doi.org/10.5281/zenodo.24189848
Primary Topic
Pharmaceutical Quality and Counterfeiting
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Counterfeit Medicines: A Major Public Health Concern and Effective Strategies to Combat the Crisis

Tushar Shelke, KIRAN BHOSALE -, Renuka Gadade
Zenodo (CERN European Organization for Nuclear Research)
Pharmaceutical Quality and Counterfeiting
article

Counterfeit Medicines: A Major Public Health Concern and Effective Strategies to Combat the Crisis

Tushar Shelke, KIRAN BHOSALE -, Renuka Gadade
article en

Abstract

Counterfeit, falsified and substandard medicines remain a major public health concern worldwide, including in India. These products may contain incorrect, insufficient or harmful ingredients, fail to provide the intended therapeutic effect, cause direct toxicity and contribute to loss of confidence in healthcare systems. The scale of the problem varies across countries and medicine categories, while differences in sampling and testing methods make prevalence estimates difficult to compare. This review discusses the terminology and classification of poor-quality medicines and summarises evidence on their global prevalence, with attention to findings from Africa and India. It examines contributing factors such as weaknesses in regulatory oversight, manufacturing and quality control, gaps in supply-chain traceability, limited access to affordable quality-assured medicines, unauthorised sales and inadequate reporting. The review also considers consequences for treatment outcomes, patient safety, healthcare costs, antimicrobial resistance and public trust. Strategies to address the problem include stronger regulatory frameworks, good manufacturing practices, secure procurement and distribution, traceability technologies, post-marketing surveillance, risk-based sampling, laboratory testing, oversight of online sales, professional training, public awareness and international information sharing. Digital authentication and portable screening tools can support detection, but should complement rather than replace appropriate quality testing and regulatory investigation. Persistent challenges include unequal regulatory capacity, complex cross-border supply chains, under-reporting and barriers to accessing reliable medicines. A coordinated, evidence-informed approach involving regulators, manufacturers, healthcare professionals and the public is needed to prevent, detect and respond to poor-quality medicines and improve access to safe, effective and quality-assured medical products.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Pharmaceutical Quality and Counterfeiting
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon